Leerink Partners Initiates Coverage on Quince Therapeutics, Inc. (QNCX) with Outperform

Market Context

Quince Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $0.95 with a market capitalization of $245.6M.

Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Quince Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Quince Therapeutics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 24, 2026	Leerink Partners	Outperform	N/A
Jun 23, 2026	Cantor Fitzgerald	Overweight	N/A
Jan 30, 2026	Citizens	Market Perform	N/A
Jan 30, 2026	D. Boral Capital	Hold	N/A
Jan 29, 2026	D. Boral Capital	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View QNCX Stock Page